(Updates)
** Shares of drug developer eFFECTOR Therapeutics Inc
EFTR.O rise 19% to $0.62
** Company announced positive interim data from a mid-stage
study evaluating combination therapy of its zotatifin in
patients with a type of breast cancer
** Says partial responses observed in 5 of 19 evaluable
patients treated with 0.07 mg/kg dose of zotatifin combined with
AstraZeneca Plc's AZN.L fulvestrant and Eli Lilly and Co's
LLY.N abemaciclib
** Adds that partial response observed in 1 of 3 patients
treated with 0.1 mg/kg dose of combined with fulvestrant
** Both combinations were generally well tolerated - EFTR
** Plans to report data from the completed dose escalation
in H2
** Stifel upgrades stock to "buy" from "hold", raises PT to
$7 from $1.3
** Separately, co
raises
$7.5 mln for 11.5 mln shares from institutional investor
** Deal values EFTR at $0.66/shr, a 23.8% premium over
last close
** Stock up 43% YTD
(Reporting by Sriparna Roy and Aditya Samal in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))